These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 3221745

  • 1. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E, Müller-Peltzer H, Hollmann M.
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [Abstract] [Full Text] [Related]

  • 2. [The bioequivalence of two oral propafenone preparations].
    Koytchev R, Alken RG, Mayer O, Böhm R, Ellrich A, Waldner-Kölblin RG.
    Arzneimittelforschung; 1995 May; 45(5):542-5. PubMed ID: 7612052
    [Abstract] [Full Text] [Related]

  • 3. Hemodynamic effects of reboxetine in healthy male volunteers.
    Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I.
    Clin Pharmacol Ther; 1999 Sep; 66(3):282-7. PubMed ID: 10511064
    [Abstract] [Full Text] [Related]

  • 4. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J.
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [Abstract] [Full Text] [Related]

  • 5. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
    Fornasini G, Monti N, Brogin G, Gallina M, Eandi M, Persiani S, Bani M, Della Pepa C, Zara G, Strolin Benedetti M.
    Chirality; 1997 May; 9(3):297-302. PubMed ID: 9176996
    [Abstract] [Full Text] [Related]

  • 6. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G, Capucci A, Strocchi E, Marchesini B, Baroni M, Frabetti L, Ambrosioni E, Magnani B.
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [Abstract] [Full Text] [Related]

  • 7. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ.
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [Abstract] [Full Text] [Related]

  • 8. Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans.
    Lim WH, Hooper WD.
    Drug Metab Dispos; 1989 Dec; 17(2):212-7. PubMed ID: 2565213
    [Abstract] [Full Text] [Related]

  • 9. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
    Cerqueira PM, Cesarino EJ, Mateus FH, Mere Y, Santos SR, Lanchote VL.
    Chirality; 1999 Dec; 11(7):591-7. PubMed ID: 10423287
    [Abstract] [Full Text] [Related]

  • 10. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [Abstract] [Full Text] [Related]

  • 11. Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites.
    Volz M, Mitrovic V, Thiemer J, Schlepper M.
    Arzneimittelforschung; 1995 Mar; 45(3):246-9. PubMed ID: 7741777
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of propafenone enantiomers in rats.
    Mehvar R.
    Drug Metab Dispos; 1990 Mar; 18(6):987-91. PubMed ID: 1981549
    [Abstract] [Full Text] [Related]

  • 13. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H, Maison Blanche P, Marchand X, Canler A, Rouesnel P, Bleinc D, Péraudeau P, Scheck F.
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
    Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ.
    J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
    [Abstract] [Full Text] [Related]

  • 15. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, Wilkinson GR.
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
    Cai WM, Zhang YD, Chen B, Cai MH, Luo JP, Ling SS.
    Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
    [Abstract] [Full Text] [Related]

  • 17. Stereoselective cardiotoxic effects of terodiline.
    Hartigan-Go K, Bateman DN, Daly AK, Thomas SH.
    Clin Pharmacol Ther; 1996 Jul; 60(1):89-98. PubMed ID: 8689817
    [Abstract] [Full Text] [Related]

  • 18. [Plasma level and action of sotalol-HCL on the ECG interval after parenteral administration in healthy subjects].
    Rehm KD, Schnelle K, Dyde CJ, Blümner E, Arendts W.
    Arzneimittelforschung; 1987 Sep; 37(9):1058-62. PubMed ID: 3435602
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans.
    Michaud V, Mouksassi MS, Labbé L, Bélanger PM, Ferron LA, Gilbert M, Grech-Bélanger O, Turgeon J.
    Ther Drug Monit; 2006 Dec; 28(6):779-83. PubMed ID: 17164694
    [Abstract] [Full Text] [Related]

  • 20. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SH, Rolan PE, Posner J.
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.